Factors Associated with Dose Determination of Radioactive Iodine Therapy for Differentiated Thyroid Cancer

被引：13
作者：
Hong C.M. [1 ,2 ]
Ahn B.-C. [1 ,2 ]
机构：
[1] Department of Nuclear Medicine, School of Medicine, Kyungpook National University, 680, Gukchaebosang-ro, Jung-gu, Daegu
[2] Department of Nuclear Medicine, Kyungpook National University Hospital, 130 Dongdeok-ro, Jung-gu, Daegu
来源：
Nuclear Medicine and Molecular Imaging | 2018年 / 52卷 / 4期
基金：
新加坡国家研究基金会;
关键词：
Differentiated thyroid cancer; High dose; I-131; Low dose; Radioactive iodine;
D O I：
10.1007/s13139-018-0522-0
中图分类号：
学科分类号：
摘要：
Radioactive iodine (RAI) therapy for differentiated thyroid cancer has been successfully used for more than 70 years. However, there is still plenty of controversy surrounding the use and doses of radioiodine. There is insufficient evidence to answer the questions. Recent American Thyroid Association (ATA) guidelines seem to favor low-dose RAI, based on recent clinical trials and meta-analyses. However, long-term follow-up data remains limited, and there are additional factors we should consider that might affect the efficacy of RAI therapy. Therefore, until sufficient data are available, it is necessary to remain cautious about determining RAI doses by considering multiple patient-specific variables. © 2018, Korean Society of Nuclear Medicine.
引用
收藏
页码：247 / 253
页数：6
相关论文
共 72 条
  • [11] Schlumberger M., Catargi B., Borget I., Deandreis D., Zerdoud S., Bridji B., Et al., Strategies of radioiodine ablation in patients with low-risk thyroid cancer, N Engl J Med, 366, pp. 1663-1673, (2012)
  • [12] Jeong S.Y., Lee S.-W., Kim H.W., Song B.-I., Ahn B.-C., Lee J., Clinical applications of SPECT/CT after first I-131 ablation in patients with differentiated thyroid cancer, Clin Endocrinol, 81, pp. 445-451, (2014)
  • [13] Doi S.A., Woodhouse N.J., Ablation of the thyroid remnant and 131I dose in differentiated thyroid cancer, Clin Endocrinol, 52, pp. 765-773, (2000)
  • [14] Hong C.M., Ahn B.-C., Jeong S.Y., Lee S.-W., Lee J., Distant metastatic lesions in patients with differentiated thyroid carcinoma. Clinical implications of radioiodine and FDG uptake, Nuklearmedizin, 52, pp. 121-129, (2013)
  • [15] Integrated genomic characterization of papillary thyroid carcinoma, Cell, 159, pp. 676-690, (2014)
  • [16] Ahn B.-C., Sodium iodide symporter for nuclear molecular imaging and gene therapy: from bedside to bench and back, Theranostics, 2, pp. 392-402, (2012)
  • [17] Ahn B.-C., Personalized medicine based on theranostic radioiodine molecular imaging for differentiated thyroid cancer, Biomed Res Int, 2016, (2016)
  • [18] Samuel A.M., Rajashekharrao B., Shah D.H., Pulmonary metastases in children and adolescents with well-differentiated thyroid cancer, J Nucl Med, 39, pp. 1531-1536, (1998)
  • [19] Luster M., Pfestroff A., Hanscheid H., Verburg F.A., Radioiodine therapy, Semin Nucl Med, 47, pp. 126-134, (2017)
  • [20] McCready V.R., Radioiodine—the success story of nuclear medicine, Eur J Nucl Med Mol Imaging, 44, pp. 179-182, (2017)
12345678